Zobrazeno 1 - 10
of 155
pro vyhledávání: '"Nazli, Dizman"'
Autor:
Marice B. Alcantara, Wilson S. Tang, Dongfang Wang, Damian Kaniowski, Elaine Kang, Nazli Dizman, Alexander Chehrazi-Raffle, Luis Meza, Zeynep Zengin, Jeremy Hall, JoAnn Hsu, Colt Egelston, Dayson Moreira, Alan Horsager, Sumanta K. Pal, Marcin Kortylewski
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
IntroductionImmune checkpoint blockade (ICB) improved clinical outcomes in renal and bladder cancer patients, but the response rates remain limited especially in metastatic disease. While STAT3 transcription factor is well-known master regulator of t
Externí odkaz:
https://doaj.org/article/dd84707eb9c14a5ba4ee11901b173fa0
Autor:
Hedyeh Ebrahimi, Dena Battle, Nicholas J. Salgia, Zeynep B. Zengin, Nazli Dizman, Luis Meza, Cristiane D. Bergerot, Regina Barragan-Carrillo, JoAnn Hsu, Daniela Castro, Benjamin Mercier, Neal Chawla, Xiaochen Li, Abhishek Tripathi, Sandy T. Liu, Alex Chehrazi-Raffle, Ulka Vaishampayan, Michael D. Staehler, Sumanta K. Pal
Publikováno v:
Nutrients, Vol 16, Iss 11, p 1630 (2024)
Many patients diagnosed with cancer adopt dietary changes and supplement use, and a growing body of evidence suggests that such modifications can affect outcomes to cancer therapy. We sought to assess the prevalence of these practices and the surroun
Externí odkaz:
https://doaj.org/article/06e6f35dc732492abffa3b9a9898817f
Autor:
Ameish Govindarajan, Nicholas J. Salgia, Haiqing Li, Daniela V. Castro, Tamara Mirzapoiazova, Brian Armstrong, Dan Zhao, Benjamin D. Mercier, Nazli Dizman, Neal Chawla, Zeynep Zengin, Luis Meza, Nishita Tripathi, Nicolas Sayegh, Alex Chehrazi-Raffle, Abhishek Tripathi, Sumanta K. Pal
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
ObjectiveTo characterize and further compare the immune cell populations of the tumor microenvironment (TME) in both clear cell and papillary renal cell carcinoma (RCC) using heavy metal-labeled antibodies in a multiplexed imaging approach (imaging m
Externí odkaz:
https://doaj.org/article/151b8f04129a483a9b5f27668a5f2782
Autor:
Cassandra Duarte, Junxiao Hu, Benoit Beuselinck, Justine Panian, Nicole Weise, Nazli Dizman, Katharine A. Collier, Nityam Rathi, Haoran Li, Roy Elias, Nieves Martinez-Chanza, Tracy L. Rose, Lauren C. Harshman, Dharmesh Gopalakrishnan, Ulka Vaishampayan, Yousef Zakharia, Vivek Narayan, Benedito A. Carneiro, Anthony Mega, Nirmish Singla, Cheryl Meguid, Saby George, James Brugarolas, Neeraj Agarwal, Amir Mortazavi, Sumanta Pal, Rana R. McKay, Elaine T. Lam
Publikováno v:
EClinicalMedicine, Vol 60, Iss , Pp 102018- (2023)
Summary: Background: Metastatic renal cell carcinoma (mRCC) is a heterogenous disease with poor 5-year overall survival (OS) at 14%. Patients with mRCC to endocrine organs historically have prolonged OS. Pancreatic metastases are uncommon overall, wi
Externí odkaz:
https://doaj.org/article/153c01ff313644d0bf2fd30f76560d5d
Autor:
Nicholas J. Salgia, Alexander Chehrazi‐Raffle, JoAnn Hsu, Zeynep Zengin, Sabrina Salgia, Neal S. Chawla, Luis Meza, Jasnoor Malhotra, Nazli Dizman, Ramya Muddasani, Nora Ruel, Mary Cianfrocca, Jun Gong, Sidharth Anand, Victor Chiu, James Yeh, Sumanta K. Pal
Publikováno v:
Cancer Medicine, Vol 10, Iss 16, Pp 5671-5680 (2021)
Abstract Background Tertiary cancer centers offer clinical expertise and multi‐modal approaches to treatment alongside the integration of research protocols. Nevertheless, most patients receive their cancer care at community practices. A better und
Externí odkaz:
https://doaj.org/article/3247895c6c634ff285bccc140d3b7306
Autor:
Chun Loo Gan, Shaan Dudani, J. Connor Wells, Frede Donskov, Sumanta K. Pal, Nazli Dizman, Nityam Rathi, Benoit Beuselinck, Flora Yan, Aly‐Khan A. Lalani, Aaron Hansen, Bernadett Szabados, Guillermo deVelasco, Ben Tran, Jae Lyun Lee, Ulka N. Vaishampayan, Georg A. Bjarnason, Mathushan Subasri, Toni K. Choueiri, Daniel Y. C. Heng
Publikováno v:
Cancer Medicine, Vol 10, Iss 4, Pp 1212-1221 (2021)
Abstract Background Cabozantinib is approved for metastatic renal cell carcinoma (mRCC) based on the METEOR and CABOSUN trials. However, real‐world effectiveness and dosing patterns of cabozantinib are not well characterized. Methods Patients with
Externí odkaz:
https://doaj.org/article/7d15b141c0ef4643936c243f3bc0a02a
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Oncologists often refer to forest plots to determine which patient subgroups may be more likely to benefit from a therapy tested in a randomized clinical trial (RCT). We sought to empirically determine the information content of subgroup
Externí odkaz:
https://doaj.org/article/b96d0f1d1c51404fa880ffbd32ad24f6
Autor:
Yu Yamamoto, Nazli Dizman, F Perry Wilson, Dennis G Moledina, Chirag R Parikh, Michael Simonov, Navid Hafez, Megan L Baker, Mark A Perazella, Anushree C Shirali, Jason Weinstein, Jeffrey M Testani, Lloyd G Cantley
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background In patients receiving immune checkpoint inhibitor (ICI) therapy, acute kidney injury (AKI) is common, and can occur either from kidney injury unrelated to ICI use or from immune activation resulting in acute interstitial nephritis (AIN). I
Externí odkaz:
https://doaj.org/article/8f30c21e89be4bcfb73a578dcc6bbadb
Autor:
Cristiane Decat Bergerot, Paulo Gustavo Bergerot, Errol J. Philip, Jo Ann Hsu, Nazli Dizman, Ulka Vaishampayan, Tanya Dorff, Sumanta Kumar Pal
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-5 (2019)
Abstract Background Despite the advent of checkpoint inhibitors (CPIs) for advanced genitourinary (GU) cancers, existing studies suggest that durable complete responses are observed in fewer than 10% of patients. This study sought to evaluate the ass
Externí odkaz:
https://doaj.org/article/d8e7825f2ef047a18c3113a531308edf
Autor:
Nazli Dizman, Matthew Austin, Bryden Considine, Shlomit Jessel, David Schoenfeld, Man Yee Merl, Michael Hurwitz, Mario Sznol, Harriet Kluger
Publikováno v:
Clinical Genitourinary Cancer. 21:221-229
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4150e7516f9a2ba24eb62832bcddf716
https://doi.org/10.1016/j.clgc.2023.01.002
https://doi.org/10.1016/j.clgc.2023.01.002